Healthcare [ 7/13 ] | Biotechnology [ 82/163 ]
NASDAQ | Common Stock
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom.
Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.
Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis.
The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research.
Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 10, 24 | -0.23 Increased by +68.06% | -0.26 Increased by +11.54% |
| Mar 28, 24 | -0.56 Increased by +22.22% | -0.48 Decreased by -16.67% |
| Nov 1, 23 | -0.66 Increased by +19.51% | -0.66 |
| Aug 8, 23 | -0.68 Decreased by -119.35% | -0.67 Decreased by -1.49% |
| May 8, 23 | -0.72 Increased by +17.24% | -0.39 Decreased by -84.62% |
| Feb 8, 23 | -0.72 Increased by +25.00% | -0.51 Decreased by -41.18% |
| Nov 8, 22 | -0.82 Increased by +8.89% | -0.78 Decreased by -5.13% |
| Aug 8, 22 | -0.31 Increased by +65.93% | -0.93 Increased by +66.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 27.36 M Increased by +2.13 K% | -31.75 M Increased by +57.53% | Decreased by -116.07% Increased by +98.10% |
| Dec 31, 23 | 4.25 M Increased by +1.82 K% | -60.45 M Increased by +18.94% | Decreased by -1.42 K% Increased by +95.79% |
| Sep 30, 23 | 2.14 M Decreased by -52.05% | -69.80 M Increased by +17.00% | Decreased by -3.26 K% Decreased by -73.11% |
| Jun 30, 23 | 957.00 K Decreased by -98.14% | -71.11 M Decreased by -485.08% | Decreased by -7.43 K% Decreased by -20.85 K% |
| Mar 31, 23 | 1.23 M Decreased by -83.24% | -74.77 M Increased by +15.02% | Decreased by -6.10 K% Decreased by -406.95% |
| Dec 31, 22 | 221.00 K Decreased by -97.07% | -74.57 M Increased by +20.11% | Decreased by -33.74 K% Decreased by -2.63 K% |
| Sep 30, 22 | 4.46 M Decreased by -16.96% | -84.09 M Increased by +0.68% | Decreased by -1.89 K% Decreased by -19.62% |
| Jun 30, 22 | 51.58 M Increased by +1.23 K% | 18.47 M Increased by +122.04% | Increased by +35.80% Increased by +101.65% |